Escolar Documentos
Profissional Documentos
Cultura Documentos
Key facts
Infections caused by resistant microorganisms often fail to respond to conventional treatment, resulting in prolonged illness, greater risk of death and higher costs. Tuberculosis strains resistant to isoniazid and rifampicin (multidrug-resistance - MDRTB) require treatment courses that are much longer and less effective. WHO estimates that there are about 630 000 MDR-TB cases in the world. Resistance to earlier generation antimalarial medicines such as chloroquine and sulfadoxine-pyrimethamine is widespread in most malaria-endemic countries. A high percentage of hospital-acquired infections are caused by highly resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) or multidrug-resistant Gram-negative bacteria. New resistance mechanisms have emerged, making the latest generation of antibiotics virtually ineffective.
Infections caused by resistant microorganisms often fail to respond to the standard treatment, resulting in prolonged illness and greater risk of death. The death rate for patients with serious infections treated in hospitals is about twice that in patients with infections caused by nonresistant bacteria.
AMR reduces the effectiveness of treatment, thus patients remain infectious for a longer time, increasing the risk of spreading resistant microorganisms to others.
AMR threatens a return to the pre-antibiotic era
Many infectious diseases risk becoming untreatable and uncontrollable, which could derail the progress made towards reaching the targets of the health-related United Nations Millennium Development Goals set for 2015.
AMR increases the costs of health care
When infections become resistant to first-line medicines, more expensive therapies must be used. The longer duration of illness and treatment, often in hospitals, increases health-care costs and the economic burden to families and societies.
AMR jeopardizes health-care gains to society
The achievements of modern medicine are put at risk by AMR. Without effective antimicrobials for care and prevention of infections, the success of treatments such as organ transplantation, cancer chemotherapy and major surgery would be compromised.
AMR threatens health security, and damages trade and economies
The growth of global trade and travel allows resistant microorganisms to be spread rapidly to distant countries and continents through humans and food.
A high percentage of hospital-acquired infections are caused by highly resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) and vancomycinor multidrug-resistant enterococciGram-negative bacteria .
Staphylococcus aureus (hospital isolates): percentage of methicillin-resistant strains, 2007, Latin America and the Caribbean pdf, 151kb
Ciprofloxacin is the only antibiotic currently recommended by WHO for the management of bloody diarrhoea due to Shigella organisms, now that widespread resistance has developed to other previously effective antibiotics. But the rapidly increasing prevalence of resistance to ciprofloxacin is reducing the options for safe and effective treatment of shigellosis, particularly for children. AMR has become a serious problem for treatment of gonorrhoea (caused by Neisseria gonorrhoeae), involving even "last-line" oral cephalosporins, and is increasing in prevalence worldwide. Untreatable gonococcal infections would result in increased rates of illness and death, thus reversing the gains made in the control of this sexually transmitted infection. New resistance mechanisms, such as enzymes produced by the bacteria that destroy last generation antibiotics, have emerged among several Gram-negative bacilli and have rapidly spread to many countries. This can render ineffective powerful antibiotics, which are often the last defense against multi-resistant strains of bacteria. This new resistant mechanism is encountered in ordinary human pathogens (e.g. Escherichia coli) that causes common infections such as urinary tract infection. Resistance to earlier generation antimalarial medicines such as chloroquine and sulfadoxinepyrimethamine is widespread in most malaria-endemic countries. Falciparum malaria parasites resistant to artemisinins are emerging in South-East Asia; infections show delayed clearance
(meaning that the parasite remains in the blood for longer), after the start of treatment and increased morbidity and mortality.
Percentage of patients with P. falciparum parasitaemia on day 3 after treatment with an artemisinin-based combination therapy (20062010) pdf, 530kb
Resistance is an emerging concern for treatment of HIV infection, after the rapid expansion in access to antiretroviral medicines in recent years; national surveys are underway to detect and monitor resistance. Because of the constantly evolving nature of influenza, resistance to antiviral drugs is continuously emerging. By 2012, virtually all circulating A viruses in humans were resistant to amantadine and rimantadine, while the frequency of resistance to the neuraminidase inhibitor oseltamivir remains low (1-2%) and no resistance to zanamivir has been detected. Antiviral susceptibility is monitored through the WHO Global Surveillance and Response System.
lack of a comprehensive and coordinated response; weak or absent antimicrobial resistance surveillance and monitoring systems; inadequate systems to ensure quality and uninterrupted supply of medicines; inappropriate use of antimicrobial medicines, including in animal husbandry; poor infection prevention and control practices; insufficient diagnostic, prevention and therapeutic tools.
WHO's response
WHO is guiding the response to AMR through:
creating policy guidance, support for surveillance, technical assistance, knowledge generation and partnerships; fostering innovation, research and development.
WHO calls on all key stakeholders, including policy-makers and planners, the public and patients, practitioners and prescribers, pharmacists and dispensers, and the pharmaceutical industry, to act and take responsibility for combating antimicrobial resistance.
WHO/S. Hollyman Misuse of medicines in people is not the only problem, however. The development of antimicrobial resistance is also driven by widespread use of antibiotics in livestock to promote growth and prevent illness. The spread of antibiotic resistance in livestock contributes to the spread of resistance in humans through food-borne illness and other routes of infection. The spread of resistance is further exacerbated by travel and population movement, making it easier for drug-resistant forms of a disease to spread to more people, and from one location to another. Antimicrobial resistance is a global problem with serious local impacts, adds Dr Sylvie Briand, Director of Pandemic and Epidemic Diseases. Conserving todays medicines for as long as possible will take action from everyone.
working to raise the awareness of antimicrobial resistance so more people involved in care-giving to both people and animals and in agriculture sectors can ensure that these medicines are used properly and appropriately; providing guidance and technical expertise to improve infection prevention and control in health-care and community settings; helping countries strengthen surveillance for early detection and their laboratory capacity for better, quicker analysis of drug resistance and its impact on the population; collaborating with other organizations, academia, civil society and industries that can join efforts to tackle the AMR threat; creating new business models to enable development of new tools to detect, treat or prevent these diseases.